Affymax
17
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
23.5%
4 terminated/withdrawn out of 17 trials
76.5%
-10.0% vs industry average
29%
5 trials in Phase 3/4
85%
11 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
Role: collaborator
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
Role: lead
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
Role: lead
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
Role: lead
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
Role: lead
Peginesatide for Anemia in Chronic Hemodialysis Patients
Role: lead
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
Role: lead
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
Role: lead
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Role: lead
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
Role: lead
Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
Role: collaborator
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
Role: collaborator
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
Role: lead
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
Role: lead
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
Role: lead
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
Role: lead
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
Role: collaborator
All 17 trials loaded